Case number 1:23-cv-00026
Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 12, 2024 | 26 | ORAL ORDER: Defendants' Motion to Dismiss for Failure to State a Claim (No. 23-26, D.I. 12, 14, 15, 19, 20, 23) is DENIED. On this record, the Court does not view the claims of the '179 patent to be directed to a patent ineligible natural phenomenon. Rather, the claims appear to be directed to a method of treating multiple sclerosis by performing certain steps, including administering a specific amount of a specific compound (fingolimod). See Vanda Pharm. Inc. v. West-Ward Pharm. Intl Ltd., 887 F.3d 1117 (Fed. Cir. 2018); see also Novartis Pharm. Corp. v. Handa Neuroscience, LLC, No. 22-353-MN, D.I. 96 (D. Del. May 10, 2022) (denying motion to dismiss complaint alleging infringement of the '179 patent because the claims appear to be directed to a patent-eligible method of treating multiple sclerosis). In accordance with the Court's August 30, 2023 Order, the parties shall meet and confer and submit an amended and consolidated case schedule for the Court's approval on or before March 26, 2024. Ordered by Judge Jennifer L. Hall on 3/12/2024. Associated Cases: 1:20-cv-00133-JLH, 1:23-cv-00026-JLH(ceg) (Entered: 03/12/2024) (0) |
| Aug 25, 2023 | 25 | STIPULATION and [Proposed] Order Regarding Case Consolidation and Pending Motion to Dismiss by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/25/2023) (5) |
| Aug 3, 2023 | 24 | STIPULATION TO EXTEND TIME for Defendant Sunshine Lake Pharma Co. Ltd. to answer, move, or otherwise respond to the Complaint to September 8, 2023 - filed by Sunshine Lake Pharma Co., Ltd.. (Stamoulis, Stamatios) (Main Document 24 replaced on 8/4/2023) (ntl). (Entered: 08/03/2023) (1) |
| Jul 13, 2023 | 23 | REPLY BRIEF re 12 MOTION to Dismiss for Failure to State a Claim filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Entered: 07/13/2023) (16) |
| Jul 6, 2023 | 22 | REDACTED VERSION of 20 Declaration by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 07/06/2023) (30) |
| Jul 6, 2023 | 21 | REDACTED VERSION of 19 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 07/06/2023) (21) |
| Jun 29, 2023 | 19 | [SEALED] ANSWERING BRIEF in Opposition re 12 MOTION to Dismiss for Failure to State a Claim filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 7/6/2023. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 18 | STIPULATION and [Proposed] Order to File Under Seal by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/29/2023) (2) |
| Jun 29, 2023 | 20 | [SEALED] DECLARATION re 19 Answering Brief in Opposition, of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Certificate of Service)(Silver, Daniel) (Entered: 06/29/2023) (0) |
| Jun 14, 2023 | 17 | STIPULATION TO EXTEND TIME to reply to Defendants HEC Pharm Co., Ltd., HEC Pharm USA Inc., CANDA HEC-1, LLC, and Rising Pharma Holdings, Inc., d/b/a Rising Pharmaceuticals, Inc.'s Motion to Dismiss to July 13, 2023 - filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Stamoulis, Stamatios) (Entered: 06/14/2023) (3) |
| Jun 5, 2023 | 16 | STIPULATION TO EXTEND TIME the Deadline for Plaintff's Response to Defendants Motion to Dismiss to June 29, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/05/2023) (2) |
| Jun 1, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Stamoulis, Stamatios) (Entered: 06/01/2023) (2) |
| Jun 1, 2023 | 13 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Burford Capital LLC for CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc. filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Stamoulis, Stamatios) (Entered: 06/01/2023) (4) |
| Jun 1, 2023 | 14 | OPENING BRIEF in Support re 12 MOTION to Dismiss for Failure to State a Claim filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc..Answering Brief/Response due date per Local Rules is 6/15/2023. (Stamoulis, Stamatios) (Entered: 06/01/2023) (26) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Main Document) (4) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 1) (30) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 2) (3) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 3) (5) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 4) (21) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 5) (16) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 6) (7) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 7) (24) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 8) (23) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 9) (3) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 10) (10) |
| Jun 1, 2023 | 15 | DECLARATION re 14 Opening Brief in Support, of Kevin Portere by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11)(Stamoulis, Stamatios) (Entered: 06/01/2023) (Exhibit 11) (30) |
| May 31, 2023 | 11 | MOTION for Pro Hac Vice Appearance of Attorney Mieke K. Malmberg, Paul J. Skiermont, Kevin P. Potere, Sarah E. Spires, and Steven J. Udick - filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc.. (Stamoulis, Stamatios) (Entered: 05/31/2023) (9) |
| Feb 17, 2023 | 10 | STIPULATION TO EXTEND TIME Rising Pharma Holdings, Inc. d/b/a Rising Pharmaceuticals, Inc.'s Deadline to Answer, Move, or Otherwise Respond to the Complaint to June 1, 2023 (from February 17, 2023) - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/17/2023) (2) |
| Feb 8, 2023 | 8 | DECLARATION of Service of HEC Pharm Co., Ltd. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/08/2023) (2) |
| Feb 8, 2023 | 9 | DECLARATION of Service of HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/08/2023) (2) |
| Feb 8, 2023 | 7 | DECLARATION of Service of Canda HEC-1, LLC by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/08/2023) (2) |
| Feb 7, 2023 | 6 | STIPULATION and [Proposed] Governing Service of Process and to Extend Time for HEC Pharm Co., Ltd., HEC Pharm USA Inc., and Canda HEC-1, LLC's Response to the Complaint by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/07/2023) (2) |
| Jan 27, 2023 | 5 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Rising Pharma Holdings, Inc. served on 1/27/2023, answer due 2/17/2023. (Joyce, Alexandra) (Entered: 01/27/2023) (2) |
| Jan 11, 2023 | 4 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (twk) (Entered: 01/11/2023) (2) |
| Jan 11, 2023 | 3 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,543,179. (twk) (Entered: 01/11/2023) (1) |
| Jan 11, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 01/11/2023) (3) |
| Jan 11, 2023 | 1 | Complaint* (1) |
